| Literature DB >> 31065018 |
Zhenhan Deng1,2, Yusheng Li3,4, Garrett R Storm5, Ronak Naveenchandra Kotian6, Xuying Sun7, Guanghua Lei2,8, Shanshan Gao9, Wei Lu10.
Abstract
Steroids are frequently used for postoperative pain relief without definite evidence. This study was conducted to assess the pain management effect of the addition of steroids to a multimodal cocktail periarticular injection (MCPI) in patients undergoing knee arthroplasty and evaluate their safety. Pubmed, Embase, and Cochrane Library were searched through April, 2018. A total of 918 patients from ten randomized controlled trials (RCTs) were ultimately included. Compared with placebo groups, steroids application could effectively relieve pain on postoperative day (POD)1; decrease C-Reactive protein (CRP) level on POD3; improve range of motion (ROM) in postoperative 5 days; reduce morphine consumption, achieve earlier straight leg raising (SLR), and shorten the length of stay (LOS) in hospital. With regards to adverse effects, it did not increase the risk of postoperative infection, postoperative nausea and vomiting (PONV), or other complications. However, no significant difference in pain relief, ROM, or increased Knee Society Knee Function Scores were found during long-term follow up. Overall, this meta-analysis ensured the efficiency and safety of steroids with MCPI in knee arthroplasty patients during the early postoperative period.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31065018 PMCID: PMC6505038 DOI: 10.1038/s41598-019-43540-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow chart of studyselection.
Characteristics of ten included RCTs.
| Study | Year of publication | Country | Surgery | Steroids group | No-Steroids group | Anaesthesia | Perioperative analgesia | Follow-up | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean age (years) | Sex (Male/female) | BMI (Kg/m2) | Intervention | N | Mean age (years) | Sex (Male/female) | BMI (Kg/m2) | Intervention | |||||||
| Chia | 2013 | Australia | TKA | 42 | 68.9 ± 8.0 | NA | 30.85 ± 5.5 | TA 40 mg (+100 ml 0.2% ropivacaine +1:1000 adrenaline) | 42 | 65.09 ± 8.4 | NA | 31.49 ± 4.7 | No TA (+others) | SA | Postopertive oral celecoxib + oxycodone, dextropropoxypheneand paracetamol | 12 weeks |
| Christian | 2009 | USA | TKA | 39 | 65.8 ± 11.1 | 16/23 | 32.9 ± 6.5 | MP 40 mg +bupivacaine 80 mg + morphine 4 mg +epinephrine 300 mg + clonidine 100 mg + cefuroxime 750 mg) | 37 | 65.2 ± 11.0 | 7/30 | 35.1 ± 8.0 | No MP (+others) | EA | Preoperative oral celecoxib + oxycodone hydrochloride/oxycodone and acetaminophen preoperatively | 12 weeks |
| Ikeuchi | 2014 | Japan | TKA | 20 | 77 ± 6 | 2/18 | NA | DA 6.6 mg (+0.75%ropivacaine + isepamicin 400 mg) | 20 | 76 ± 3 | 4/16 | NA | No DA (+others) | GA | Postoperative PCA + oral loxoprofen + fentanyl injection | 12 weeks |
| Kim | 2015 | Korea | TKA | 43 | 71.4 ± 4.7 | 41/2 | 25.8 ± 3.3 | MP 40 mg (+ropivacaine 180 mg + morphine 5 mg + ketorolac30 mg) | 45 | 70.6 ± 5.5 | 39/4 | 27.2 ± 4.0 | No MP (+others) | SA | Preoperative oral celecoxib + tramadol; Postoperative PCA + oral celecoxib + tramado + pethidineintramuscular injection (rescue) + oral oxycodone (rescue) | 1 week |
| Kwon | 2014 | Korea | TKA | 76 | 69.3 (62–77) | 0/76 | 25.9 (22–32) | TA 40 mg (+morphine 10 mg + ropivacaine 300 mg + ketorolac 30 mg + 1:1000 of epinephrine300 ug) | 76 | 69.3 (62–77) | 0/76 | 25.9 (22–32) | No TA (+others) | SA | PostoperativePCA + oral celecoxib and ultracet + ketoprofenintramuscular injection (rescue) | 6 months |
| Ng | 2011 | Singapore | UKA | 41 | 63 (53–71) | 10/31 | 28 (23–32) | TA 40 mg (+0.5% bupivacaine + 1:200,000 epinephrine) | 42 | 62 (55–70) | 11/31 | 27 (21–32) | No TA (+others) | SA or GA | Postoperative PCA + oral Synflex + oral amotidine | 6 months |
| Pang | 2008 | Singapore | UKA | 45 | 68 (54–80) | 8/37 | 27.3 ± 6.1 | TA 40 mg (+0.5 ml/kg of 1:200,000 epinephrine + 0.5% bupivacaine) | 45 | 67 (44–80) | 8/37 | 27.5 ± 5.6 | No TA (+others) | SA or GA | Postoperative PCA + oral naproxen | 2 years |
| Seah | 2011 | Singapore | TKA | 29 | 67.9 | NA | 26.7 | TA 40 mg (+0.5 ml/kg of 1:200,000 epinephrine + 0.5% bupivacaine) | 30 | 65.4 | NA | 27.3 | No TA (+others) | SA or GA | Postoperative PCA + oral naproxen | 2 years |
| Tsukada | 2016 | Japan | TKA | 38 | 75 (58–88) | 5/35 | 26.7 (20.5–38.6) | MP 40 mg (+ropivacaine 300 mg + morphine 8 mg + epinephrine 0.3 mg + ketoprofen 50 mg | 37 | 72 (47–88) | 32/5 | 27.3 (18.4–40.6) | No MP (+others) | SA | Postoperative oral loxoprofen + diclofenacsodium (rescue) | 1 year |
| Yue | 2013 | China | TKA | 36 | 70.2 ± 6.4 | 32/4 | 25.23 ± 4.81 | BA 1 mg (+30 ml 0.75% ropivacaine + 0.5 ml1:1000 adrenaline) | 36 | 69.3 ± 5.7 | 32/4 | 26.14 ± 3.27 | No BA (+others) | GA | Preoperative celecoxib; Postoperative PCA + oral celecoxib + morphine intramuscular injection (rescue) | 1 year |
Surgery: TKA, total knee arthroplasty; UKA, unicondylar knee arthroplasty.
Intervention: BA, betamethasone; DA, dexamethasone; MP, methylprednisolone; TA, triamcinoloneacetonide.
Anaesthesia: SA, spinal anaesthesia; EA, endotracheal anaesthesia; GA, general anaesthesia.
Perioperative analgesia: PCA, patient-controlled analgesia.
NA, not available.
Methodological quality assessment according to the Cochrane Collaboration’s Risk of Bias tool study.
| Study | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other bias |
|---|---|---|---|---|---|---|---|
| Chia | + (a) | +* | + | + | + | + | ? |
| Christian | + (b) | ? | + | + | + | + | ? |
| Ikeuchi | + (c) | +* | + | + | + | + | ? |
| Kim | ? | ? | + | + | + | + | ? |
| Kwon | ? | ? | + | + | + | + | ? |
| Ng | ? | ? | + | + | + | ? | ? |
| Pang | + (d) | ? | + | + | + | + | ? |
| Seah | + (d) | +* | + | + | + | + | ? |
| Tsukada | + (c) | +* | + | + | + | + | ? |
| Yue | ? | ? | + | + | ? | + | ? |
+, low risk of bias; −, high risk of bias; ? unclear risk of bias.
Random sequencegeneration: a, random number generator; b, block randomization; c, random numbers; d, randomization table.
Allocationconcealment: *sealed envelopes.
Figure 2Forest plot diagram showing VAS at POD1 (a), POD3 (b), POW2 (c).
Figure 3Forest plot diagram showing ROM at various time points after knee joint arthroplasty.
Figure 4Forest plot diagram showing postoperative morphine consumption (a), CRP at POD3 (b), the interval to perform SLR postoperatively (c), LOS (d), KSS knee score (e) and function score (f) at POW6.
Figure 5Forest plot diagram showing total incidence of complications (a), incidence of infection (b) and PONV (c) after knee joint arthroplasty.
Results of Meta-Analysis.
| Outcomes | Studies | No. of Patients | OR or MD (95% CI) | Heterogeneity (I2), % |
|
|---|---|---|---|---|---|
|
| |||||
| POD1 | 3 | 190 | −1.52 (−2.94, −0.10) | 82 | 0.04 |
| POD3 | 2 | 110 | −0.83 (−2.30, 0.64) | 76 | 0.27 |
| POW2 | 2 | 124 | −0.42 (−1.19, 0.35) | 14 | 0.29 |
|
| |||||
| POD1 | 4 | 324 | 11.57 (9.85, 13.30) | 47 | <0.00001 |
| POD2 | 3 | 248 | 9.03 (6.67, 11.38) | 0 | <0.00001 |
| POD3 | 2 | 165 | 5.73 (0.85, 10.60) | 44 | 0.02 |
| POD4 | 2 | 165 | 5.53 (0.68, 10.38) | 40 | 0.03 |
| POD5 | 2 | 165 | 5.90 (0.87, 10.93) | 0 | 0.02 |
| POW1 | 2 | 227 | 1.46 (−1.21, 4.13) | 0 | 0.28 |
| POW2 | 2 | 160 | −1.27 (−5.83, 3.29) | 0 | 0.59 |
| POW4 | POW1 | POW1 | POW1 | POW1 | POW1 |
| POW6 | 3 | 313 | 0.91 (−1.65, 3.47) | 14 | 0.49 |
| POM3 | 4 | 326 | 0.19 (−6.79, 7.17) | 93 | 0.96 |
| POM6 | 3 | 248 | 1.84 (−1.41, 5.08) | 81 | 0.27 |
| Morphine consumption | 3 | 206 | −7.94 (−14.35, −1.53) | 73 | 0.02 |
| CRP | 2 | 123 | −4.82 (−7.41, −2.23) | 84 | 0.0003 |
| SLR | 3 | 282 | −0.65 (−0.86, −0.44) | 43 | <0.00001 |
| LOS | 2 | 159 | −0/98 (−1.25, −0.71) | 0 | <0.00001 |
|
| |||||
| Knee scores | 2 | 228 | 0.54 (−0.64, 1.72) | 0 | 0.37 |
| Function scores | 2 | 228 | −2.47 (−11.62, 6.68) | 56 | 0.60 |
| Complications | 10 | 820 | 1.07 (0.63, 1.82) | 0 | 0.81 |
| Infection | 3 | 225 | 1.29 (0.31, 5.38) | 0 | 0.72 |
| PONV | 4 | 352 | 0.78 (0.46, 1.34) | 0 | 0.37 |